Send to

Choose Destination
Curr Drug Targets. 2019 Aug 21. doi: 10.2174/1389450120666190821160207. [Epub ahead of print]

Advances in Current Diabetes Proteomics: From the Perspectives of Label-free Quantification and Biomarker Selection.

Author information

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058. China.



Due to its prevalence and negative impacts on both economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification proteomics (LFQ) and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel protein biomarkers, and discover innovative therapeutic protein targets.


The purpose of this manuscript is to review and analyze the recent computational advances and development of label-free quantification and diabetic marker selection in diabetes proteomics.


Web of Science database, PubMed database and Google Scholar were utilized for searching label-free quantification, computational advances, feature selection and diabetes proteomics.


In this study, we systematically review the computational advances of label-free quantification and diabetic marker selection which be applied to get understanding of DM pathological mechanisms. Firstly, different popular quantification measurements and proteomic quantification tools which have been applied to the diabetes studies are comprehensively discussed. Secondly, a number of popular manipulation methods including transformation, pretreatment (centering, scaling, and normalization), missing value imputation methods and a variety of popular feature selection techniques applied to diabetes proteomic data are overviewed with objective evaluation on their advantages and disadvantage. Finally, the guidelines for the efficient use of the computation-based LFQ technology and feature selection methods in diabetes proteomics are proposed.


In summary, this review provides guidelines for researchers who will engage in proteomics biomarker discovery and by properly applying these proteomic computational advances, more reliable therapeutic targets will be found in the field of diabetes mellitus.


Antidiabetic drug; Computation; Diabetes proteomics; Label free quantification; Mass spectrometry; Target discovery

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center